Related Experiment Videos
[How to improve drug development and utilization in pediatrics]
G Pons1, C Lassale, E Eschwege
1Hôpital Saint-Vincent de Paul, Paris, France.
Insights
Pediatric drug evaluation is crucial due to insufficient research and a lack of suitable formulations. New regulations and research networks aim to improve the safe and effective use of medications in children.
Area of Science:
- Pediatric Pharmacology
- Drug Safety and Efficacy
- Regulatory Science
Background:
- Unlicensed and off-label prescriptions are common in pediatric populations due to insufficient drug evaluation.
- Lack of adapted pharmaceutical formulations contributes to challenges in pediatric drug use.
Purpose of the Study:
- To highlight the importance of drug evaluation in children.
- To discuss the implications of new regulations and research initiatives in pediatric pharmacology.
- To identify needs for improved drug utilization in pediatric patients.
Main Methods:
- Review of current regulatory landscape concerning pediatric drug evaluation.
- Description of the establishment of pediatric pharmacology research networks.
- Discussion of essential components for appropriate pediatric drug use.
Main Results:
- A new US Food and Drug Administration (FDA) regulation mandates manufacturers assess new drugs in pediatric patients.
- Creation of a ten-center American Pediatric Pharmacology Research Unit network.
- Emerging similar trends in Europe indicate a growing focus on pediatric drug research.
Conclusions:
- Improved drug evaluation, adapted formulations, and administration devices are essential for pediatric patients.
- Enhanced knowledge on long-term consequences of drug use during child development is necessary.
- Regulatory changes and dedicated research networks are vital for advancing pediatric pharmacology.
Abstract:
Insufficient drug evaluation in children and the lack of adapted pharmaceutical formulations explain the importance of unlicensed and off-label prescriptions. As a consequence a regulation proposed in the USA by the Food and Drug Administration, requiring manufactures to assess the safety and effectiveness of new drugs in paediatric patients, has recently been adopted. Appropriate means to facilitate drug evaluation in children are now necessary in terms of recruitment and methodology. A ten-centre American Pediatric Pharmacology Research Unit network has been created and is being financed by the National Institute of Health. A similar trend is evolving in Europe. Appropriate drug utilization in children requires adequate formulations, administration devices and information as well as improved knowledge on the long-term potential consequences of drug use during growth and maturation.